John Rah > DLA Piper LLP (US) > New York, United States > Lawyer Profile

DLA Piper LLP (US)
1251 AVENUE OF THE AMERICAS
NEW YORK, NY 10020-1104
United States
John Rah photo

Work Department

Litigation, Arbitration and Investigations; FDA

Position

Partner

Career

John Rah advises pharmaceutical and medical device manufacturers, healthcare providers and suppliers and managed healthcare organizations on corporate compliance program development and operations designed to mitigate the risk of fraud and abuse.

John counsels clients on investigations and informal inquiries by the US Department of Justice (DOJ) and the US Department of Health and Human Services Office of Inspector General (OIG). His work also includes conducting internal investigations for health care companies involving potential violations of relevant policies and procedures designed to ensure compliance with the anti-kickback, Food Drug and Cosmetics Act .

John also has a deep background in negotiating and implementing Corporate Integrity Agreements (CIAs), Deferred Prosecution Agreements (DPAs), and state consent decrees, and regularly interacts with the OIG and other relevant agencies in connection with these integrity agreements.

Education

J.D., Georgetown University; B.A., New York University

Lawyer Rankings

United States > Dispute resolution > Corporate investigations and white-collar criminal defense

The team at DLA Piper LLP (US) is able to draw on the firm’s global network to handle government investigations and enforcement matters involving multiple jurisdictions. In 2018, the Dallas office was joined by Jason Hopkins and Jason Lewis from Greenberg Traurig LLPJoel Athey joined in Los Angeles from Holland & Knight LLPJeffrey Tsai joined in San Francisco from Alston & Bird LLP and the Chicago office welcomed Matt Hiller from the DOJ. Highlights for Washington DC’s John Rah included assisting Pfizer with the negotiation of a Corporate Integrity Agreement with the DOJ to resolve allegations that donations the client made to independent charity patient assistant programs were improper. In another standout matter, New York’s Karl Buch represented the Audit Committee of Cognizant Technology Solutions, successfully convincing the DOJ to decline charges following an investigation into potential FCPA violations; in a parallel case, he secured a settlement with the SEC in administrative proceedings. Gail Rodgers is engaged by GlaxoSmithKline on a number of government and internal investigations. The team is chaired by Jonathan King in Chicago and John Hillebrecht in New York; Jessica Masella in New York is also a name to note.